|
Price: $186.9400
$-13.07 
-6.535%
|
| Day's High:
| $200.01
| Week Perf:
| -4.17 %
|
| Day's Low: |
$ 186.78 |
30 Day Perf: |
2.1 % |
| Volume (M): |
601 |
52 Wk High: |
$ 277.34 |
| Volume (M$): |
$ 112,370 |
52 Wk Avg: |
$216.18 |
| Open: |
$199.31 |
52 Wk Low: |
$148.00 |
|
|
| Market Capitalization (Millions $) |
7,252 |
| Shares
Outstanding (Millions) |
39 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
1,134 |
| Net Income (TTM) (Millions $) |
14 |
| Cash Flow (TTM) (Millions $) |
174 |
| Capital Exp. (TTM) (Millions $) |
17 |
Penumbra Inc
Penumbra Inc. is a California-based medical device company that's focused on the development and manufacturing of innovative medical technologies for the treatment of neurological and vascular disorders. The company's portfolio of products includes neurovascular access, neurovascular intervention, neurointensive care, and related products for stroke and neurovascular disorders, including cerebral aneurysms, intracranial atherosclerosis, and traumatic brain injury.
Penumbra's history can be traced back to 2004 when it was founded by Dr. Adam Elsesser, an entrepreneur with a background in neuroscience and neurointervention. The company's name derives from the Latin word "penumbra," which refers to the partial shadow surrounding an area of complete darkness, symbolizing Penumbra's mission to bring light to dark and complex medical issues.
The company's flagship product, the Penumbra System, is a mechanical thrombectomy device that's used to remove blood clots from the brain during an ischemic stroke. This device has been a game-changer in the treatment of stroke, providing a safe and efficient alternative to traditional clot-busting drugs. Other notable products in Penumbra's portfolio include the 3D Revascularization Device, which provides mechanical support for the stent during large-vessel or complex aneurysm treatment, and the Neuron MAX System, which is used for rapid sealing of puncture holes following diagnostic or interventional neurovascular procedures.
In addition to its portfolio of medical devices, Penumbra has also developed a line of neurointensive care products, including catheters, drainage systems, and other devices that aid in the management of critically ill patients with neurological disorders. These products are designed to optimize patient outcomes and reduce complications during the recovery process.
Penumbra is committed to innovation and invests heavily in research and development to advance the quality and efficacy of its products. The company's state-of-the-art manufacturing and research facilities are located in Alameda, California, and its products are sold in over 100 countries worldwide.
Penumbra has won numerous awards and recognitions for its contributions to the field of medical technology, including the Galien USA Award for Best Medical Technology in 2011 and 2015. The company's commitment to excellence and innovation has helped make it a leader in the medical device industry and a driving force in the fight against neurovascular disorders.
Company Address: One Penumbra Place Alameda 94502 CA
Company Phone Number: 748-3200 Stock Exchange / Ticker: NYSE PEN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Penumbra Inc
In recent financial news, the Medical Equipment & Supplies company, Penumbra Inc, has reported a strong fiscal period with impressive growth in net profit per share and revenue. Net profit per share increased by 27.27% to $0.28 per share, while revenue improved by 15.434% to $278.66 million compared to the prior year period. This growth outpaced most of the company's contemporaries in the Medical Equipment & Supplies sector, with the sector averaging a 6.11% business advance in the first quarter of 2024.
Despite a decrease in earnings per share and revenue from the previous reporting period, Penumbra Inc saw significant growth in net profits, with $11.002 million reported in the January to March 31 2024 timeframe, an increase of 28.5% from the same timeframe a year ago. The company also highlighted improving profit margins, with net margin rising to 3.95% and operating margin edging up to 4.34%. Operating earnings rose by 51.11% to $12.101 million.
|
| Penumbra Inc
The recently released financial results of Penumbra Inc for the fiscal year ending on December 31, 2023, have revealed an impressive growth trajectory for the company. With a substantial increase in net profit per share and revenue, improved profit margins, and notable changes in inventory and accounts receivable levels, Penumbra Inc is well-positioned to navigate the competitive landscape of the Medical Equipment & Supplies industry.
I. Stellar Financial Performance:
In the Dec 31, 2023, report, Penumbra Inc showcased outstanding results. The net profit per share experienced a remarkable growth rate of 1207.82% year-on-year, reaching $1.33 per share. Moreover, the revenue witnessed a significant boost of 28.688%, reaching $284.68 million. These figures demonstrate the company's ability to generate substantial returns for its shareholders while increasing its market presence.
|
| Penumbra Inc
Penumbra Inc Reports Astonishing Revenue Growth and Improved Profitability in Q3 2023
Penumbra Inc, a renowned medical equipment and supplies company, recently announced its financial results for the third quarter of 2023. The company experienced a significant surge in revenue, leading to a commendable turn into profitability. With revenue growing by an impressive 26.801% to $270.95 million, Penumbra Inc showcased its strong performance in contrast to the previous financial period ending September 30, 2022, where earnings per share were at $0.23 compared to a loss of $-0.06.
In comparison to its competitors in the medical equipment and supplies industry, Penumbra Inc's revenue growth in the third quarter of 2023 stands out positively. While the overall industry reported a 2.66% top-line advance during the same period, Penumbra Inc's surge in revenue amounted to 3.613%. This achievement reflects the company's ability to adapt to market demands and effectively fulfill customer needs while maintaining profitability.
|
| Penumbra Inc
Penumbra Inc., a medical equipment and supplies company, has recently reported astonishing revenue growth, leading to a surge in profitability. The company's revenue grew by an impressive 25.513% to reach $261.50 million. This significant increase in revenue is accompanied by a rise in earnings per share, which reached $0.48 compared to -$0.10 in the same period the previous year.
The growth exhibited by Penumbra Inc. is particularly noteworthy, as it stands in contrast to the rest of the medical equipment and supplies industries, which experienced a decline of -0.01% in their top-line revenue. On top of that, the company's earnings per share saw an extraordinary improvement of 118.18%, rising from $0.22 to the current level. Furthermore, their revenue increased by 8.327% from $241.40 million.
|
| Penumbra Inc
Penumbra Inc's return on average invested assets (ROI) of 0.54% in its first quarter of 2023 is lower than the company's average ROI of 1.81%. However, the ROI has improved compared to the fourth quarter of 2022, when it was -0.17%, thanks to the growth of net income.
While 43 other companies in the healthcare sector had a higher ROI, Penumbra Inc's overall ROI ranking has improved significantly from the fourth quarter of 2022, moving from 2925 to 608 in the March 31, 2023 quarter.
|
| Per Share |
Current |
| Earnings (TTM) |
0.29 $ |
| Revenues (TTM) |
29.22 $
|
| Cash Flow (TTM) |
4.49 $ |
| Cash |
8.76 $
|
| Book Value |
29.93 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.29 $
|
| Revenues (TTM) |
29.22 $ |
| Cash Flow (TTM) |
4.49 $ |
| Cash |
8.76 $
|
| Book Value |
29.93 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 72.87 % |
of total Revenue |
| International |
|
27.13 % |
of total Revenue |
| Thrombectomy |
|
67.97 % |
of total Revenue |
| Embolization and Access |
|
32.03 % |
of total Revenue |
|
|
